Company intelligence / Profile preview

Bionime

Ownership: Public · 4737
Employees: ~501
Development stage: Commercial

Overview

Bionime has developed and commercialized a range of blood glucose monitoring systems using patented noble metal biosensor technology. Their products have demonstrated high accuracy and precision in independent clinical studies and are distributed globally under the Rightest brand as well as private labels. The company also entered a licensing agreement with GE to provide GE-branded diabetes solutions. No clinical trial results are relevant since these are diagnostic devices rather than therapeutics.

Therapeutic areas: Endocrinology
Modalities: DeviceBiosensor technologyDiagnostic device
Industry: Physiological Monitoring

Partnerships

General Electric (GE) – global licensing agreement for GE-branded diabetes solutions

Beyond the preview

Go deeper on Bionime.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionime.

Explore the full profile